TAPI-1 is an ADAM17/TACE inhibitor that suppresses the release of soluble TNF-alpha, p60TNFR, and IL-6R from unstimulated and PMA-induced monocytic cell lines (e.g., THP-1) and human peripheral blood mononuclear cells; it inhibits TACE-dependent constitutive shedding of co-transfected APP(695); attenuates AngII-induced EGFR transactivation and cell proliferation in the human hematopoietic stem cell line LI90; and, in combination with the EGFR inhibitor AG1478, inactivates the AREG/EGFR/ERK signaling pathway and reduces pro-inflammatory cytokine release in pSS salivary gland-derived epithelial cells. TAPI-1 also acts as a Matrix Metalloproteinase (MMP) inhibitor.